Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is...
Những tác giả chính: | Andersson, U, Smith, D, Jeyakumar, M, Butters, T, Borja, M, Dwek, R, Platt, F |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2004
|
Những quyển sách tương tự
-
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
Bằng: Ulrika Andersson, et al.
Được phát hành: (2004-08-01) -
NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
Bằng: Jeyakumar, M, et al.
Được phát hành: (2004) -
N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
Bằng: Andersson, U, et al.
Được phát hành: (2000) -
N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
Bằng: Baek, R, et al.
Được phát hành: (2004) -
N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Bằng: Baek, R, et al.
Được phát hành: (2008)